CAS Number: 1381321-73-2
Therapeutic Category
Non-alcoholic Steatohepatitis
API Technology
Small molecule
Dose Form
Oral Solid/Tablets
Dr Reddy's Development Status
Under-Development
Resmetirom works by specifically targeting the thyroid hormone receptor beta (THR-β) in the liver. Here's a breakdown of the key aspects:
Selective THR-β Activation: Unlike natural thyroid hormones or some drugs, Resmetirom primarily activates THR-β and has minimal effect on THR-α, another thyroid hormone receptor found throughout the body. This targeted action helps minimize potential side effects outside the liver.
Promoting Fatty Acid Metabolism: In a healthy liver, fatty acids are broken down for energy or eliminated. NASH is characterized by an accumulation of fat. Resmetirom activation of THR-β stimulates enzymes involved in fatty acid degradation and oxidation, leading to a reduction in liver fat content.
Potential Anti-inflammatory Effects: While the exact mechanism is still under investigation, THR-β activation by Resmetirom might also play a role in reducing inflammation in the liver, a hallmark of NASH. This could further contribute to improved liver function.
Resmetirom is approved for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis in adults. NASH is a liver condition characterized by fat accumulation, inflammation, and fibrosis (scarring). Resmetirom helps improve liver function by reducing fat and potentially inflammation.
Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Resmetirom API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.
Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Resmetirom API is the outcome of the extensive expertise in R&D, IP, and Regulatory.
A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.
No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.
Sign-up for our email service to get Market and Product insights and updates right to your digital doorstep
The categories of personal information collected in this form include name, company, and contact information etc. The personal information collected will be used for exploratory discussions on contract manufacturing, marketing and to perform research and analytics and others. For more information about the categories of personal information collected by Dr.Reddy's and the purposes for which Dr.Reddy's uses personal information, visit https://api.drreddys.com/privacy-policy.
No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.